TACE is thought to increase neoantigen release as well as local tumour programmed cell death ligand 1 (PD-L1) expression, leading to the hypothesis that combinations with anti-programmed cell death 1 (PD-1) or anti-PD-L1 ICIs might increase antitumour responses.26 This evidence concerns the gene PDCD1 and neoplasm.